Skip to content

Educational reference only. Not medical advice, diagnosis, or treatment, and not dosing, injection, or purchasing guidance.Medical disclaimer

Import Alert 66-80

The description below is from FDA’s GLP-1 concerns page, which names import alert 66-80. The alert document itself was not parsed into this page, so the green list of firms is not copied.

  • FDA says it established a green-list import alert (66-80) to help stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the U.S. supply chain.
  • FDA says the alert does not apply to GLP-1 API from manufacturers that, based on an FDA inspection or other FDA evaluation, appear to comply with FDA manufacturing standards.
  • FDA says the action does not stop legal importation from compliant API manufacturers and does not create new limits on legal compounding of GLP-1 drugs.

Product codes, firm names, and the alert’s revision history have to be read on the import-alert page. They are not reproduced here.

This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.

Page record

  • Type: Regulation
  • Domain: peptides
  • Evidence: Not rated
  • Status: reviewed
  • Last reviewed: 2026-11-20

Regulatory status: U.S. FDA Import Alert 66-80, as described on FDA's unapproved GLP-1 drug page. Firm-level green list not copied.

Sources

Referenced by

A link from another wiki page is not evidence. Facts should point at the sources above.